-

Purdue Pharma Statement with Respect to District Court Decision Vacating Bankruptcy Court’s Confirmation of the Plan of Reorganization

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. today announced its intent to appeal today’s ruling by the United States District Court for the Southern District of New York, which vacated the Bankruptcy Court’s September 2021 order confirming its chapter 11 plan of reorganization (the “Plan”). The company will simultaneously continue its efforts to forge yet further consensus around a Plan that will deliver billions of dollars to the American people for opioid abatement. The current Plan enjoys overwhelming support, including from every one of the many ad hoc creditor groups in the case and more than 95% of Purdue’s over 120,000 voting creditors, including 43 states and territories. Fewer than 20 stakeholders appealed.

Contrary to more than 30 years of governing precedent approving third party releases in appropriate circumstances, the District Court held that third party releases are never authorized by the Bankruptcy Code outside of the asbestos context.

“While the district court decision does not affect Purdue’s rock-solid operational stability or its ability to produce its many medications safely and effectively, it will delay, and perhaps end, the ability of creditors, communities, and individuals to receive billions in value to abate the opioid crisis,” said Steve Miller, Chairman of the Purdue Pharma L.P. Board of Directors. “These funds are needed now more than ever as overdose rates hit record-highs, and we are confident that we can successfully appeal this decision and deliver desperately needed funds to the communities and individuals suffering in the midst of this crisis.”

Purdue’s Plan of Reorganization was developed through more than two years of collaborative efforts in an inclusive process that saw governments, creditors, and representatives of individual victims come together to forge a solution that serves the public interest.

Please click here for more information on Purdue’s Plan.

Contacts

Media:
Michele Sharp
(203) 588-7584

Purdue Pharma L.P.

Details
Headquarters: Stamford, CT
CEO: Dr. Craig Landau
Employees: 550
Organization: PRI

Release Versions

Contacts

Media:
Michele Sharp
(203) 588-7584

More News From Purdue Pharma L.P.

Tinostamustine Shows Early Signals of Activity in Phase 1 Glioblastoma Trial

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. (“Purdue”) announced positive preliminary results from a Phase 1 study of tinostamustine in MGMT promoter-unmethylated (uMGMT) glioblastoma (GBM), a form of aggressive brain cancer with a subset of patients that do not respond or respond poorly to standard-of-care therapy. Tinostamustine was shown to be tolerable at doses of 80 to 100 mg/m², with side effects similar to other anti-neoplastic agents and preliminary signs of efficacy. The resul...

Bankruptcy Court to Confirm Purdue Pharma’s Plan of Reorganization

STAMFORD, Conn.--(BUSINESS WIRE)--The United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) today indicated it will approve the Chapter 11 Plan of Reorganization (The “Plan”) for Purdue Pharma L.P. (“Purdue”). The Plan, which achieved remarkable consensus with the support of more than 99% of voting creditors, will deliver billions in urgently needed funding for opioid crisis abatement and victim compensation, as well as rescue medicines that will save liv...

FDA Grants Orphan Drug Designation for Tinostamustine in Malignant Glioma

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. (“Purdue”) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pipeline drug tinostamustine for the treatment of malignant gliomas, a broad category of brain and spinal cord cancers that affect both adults and children and includes rapidly growing, invasive tumors like glioblastoma. As many as 22,000 people are diagnosed with malignant gliomas annually in the United States1. FDA gr...
Back to Newsroom